Celcuity (NASDAQ:CELC) Given Buy Rating at HC Wainwright

Celcuity (NASDAQ:CELC - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 154.48% from the company's current price.

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a research note on Thursday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $30.80.

Celcuity Price Performance

CELC stock opened at $10.61 on Monday. The business has a fifty day moving average of $10.15 and a two-hundred day moving average of $11.64. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $401.47 million, a price-to-earnings ratio of -4.07 and a beta of 0.56. Celcuity has a 52-week low of $7.58 and a 52-week high of $19.77.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. As a group, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently modified their holdings of CELC. GAMMA Investing LLC grew its stake in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after purchasing an additional 1,225 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Celcuity during the 4th quarter worth $50,000. Focus Financial Network Inc. acquired a new position in Celcuity during the 1st quarter worth $108,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Celcuity during the 4th quarter worth $142,000. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.